Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CKD-846 in Healthy Male Subjects
NCT07404735Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-846 in benign prostatic hyperplasia (BPH) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Plasma Concentration of D091 and Plasma Concentration of CKD-846. Started Feb 2026; status: completed.
02
Drugs
CKD-846
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07404735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404735.